摘要
目的:总结PET/CT在肺癌治疗中的应用价值。方法:应用PubMed和CNKI期刊全文数据库检索系统,以"PET/CT、肺癌和早期"为关键词,检索2000-01-2011-12相关文献。纳入标准:1)PET/CT的应用;2)肺癌的早期诊断、治疗和预后。根据纳入标准,最后纳入分析43篇。结果:PET/CT作为一种有效的无创性显像诊断技术,实现了功能影像和解剖影像的融合,对肺癌早期诊断的敏感性、特异性和准确性为85%～96%、83%～100%和84%～94%,临床分期分别为78%～94%、84%～96%和81%～95%,疗效评价分别为85%～100%、82%～96%和75%～90%。治疗决策使约30%～50%分期改变,10%～25%分期下降,20%～35%分期上升。预后预测PET/CT检查阴性患者生存期明显长于阳性患者,中位生存期是24～34个月长于11～12个月。PET/CT对肺癌早期诊断孤立性结节的敏感性、临床分期的准确性、纵隔淋巴结清除方式的合理选择、放疗计划的精确制定、早期疗效评价及预后预测提供了更为准确的依据。结论:PET/CT在肺癌早期诊断、分期、治疗、疗效评价及预后中的应用将具有更好的发展前景。
OBJECTIVE： To summarize the application value of PET/CT in lung cancer. METHODS： PET/CT, lung cancer,early were searched as key words in the database of PubMed and CNKI from January 2000 to December 2011. Forty-three literatures were finally screened out according to the inclusion criteria as follows： 1 ）the application of PET/CT ; 2） early diagnosis, treatment, prognosis of lung cancer. RESULTS： As a noninvasive imaging diagnosis technolo- gy, PET/CT can realize the fusion of functional and anatomical image effectively, the sensitivity, specific, accuracy of early diagnosis of lung cancer were 85%-- 96%,83%/00 -- 100%,84%-- 94%. Clinical staging were 780/00 -- 94%,84% -- 96%, 81 ~ -- 95 %. Efficacy evaluation were 85 % -- 100 %, 82 % -- 96 %,75 % -- 90 %. Treatment decision Make stage is changed about 30 %-- 50 %, stage is declined about 10 % -- 25 %, stage rise about 20 % -- 35 %. The survival period of PET/CT rega- rive patients is significantly longer than that of positive patients. The median survival time was 24--34 months versus 11 -- 12 monlhs. CONCLUSION： PET/CT will have better prospects in the clinical appplications for early diagnosis, stage, treatment,assessment of efficacy and prognosis of lung cancer.
出处
《中华肿瘤防治杂志》
CAS
北大核心
2013年第5期392-395,400,共5页
Chinese Journal of Cancer Prevention and Treatment
基金
山东省自然科学基金(CY2008C150)
关键词
PET
CT
肺癌
早期
诊断和治疗
综述文献
PET/CT
lung cancer early diagnosis and treatment review literture
